The Prostate Cancer Dilemma. Selecting Patients for Active Surveillance, Focal Ablation and Definitive Therapy

Description

This text provides a comprehensive, state-of-the art review of this field, and will serve as a valuable resource for clinicians, surgeons and researchers with an interest in early prostate cancer. The book reviews new data about genetic markers, transperineal mapping biopsy and mpMRI, how to apply each of these technologies in patients with elevated PSA, when a prior prostate biopsy performed by the standard TRUS method is negative and in cases where low risk disease is already diagnosed, how to differentiate those men who might harbor more aggressive disease from those who do not. Over 75% of newly diagnosed prostate cancer meets the criteria for low risk disease which has created a dilemma for both patients and clinicians. Active surveillance programs have been initiated and are reviewed. How the new technologies impact surveillance programs is addressed. Clinical stage designation is updated and a new intra-prostatic staging system is discussed. Prostate biopsy techniques utilizing transrectal ultrasound, transperineal mapping, elastography and mpMRI are compared. Finally, utilization of this new technology in the application of focal therapy is reviewed.

The Prostate Cancer Dilemma will serve as a very useful resource for physicians and researchers dealing with, and interested in this challenging malignancy. Chapters are written by experts in their fields and include the most up to date scientific and clinical information as well as links to procedural video content.

Feature:

• Written by experts in their fields
• Provides links to procedural video content
• Richly illustrated with color photographs, illustrations and tables

Contents

Part One: Diagnosis

Chapter 1: History of Prostate Specific Antigen, from Detection to Over Diagnosis
Brandon J. Manley and Gerald L. Andriole

Chapter 2: Pathology of Prostate Cancer: What Has Changed in the Last 30 Years
M. Scott Lucia

Chapter 3: Clinical Risk Prediction Tools for Prostate Cancer: TNM to CAPRA - Should Risk be Re-Defined?
Michael S. Leapman and Matthew R. Cooperberg

Chapter 4: TRUS Biopsy: Is There Still a Role?
Michael S. Leapman and Katsuto Shinohara

Chapter 5: Transperineal Biopsy Technique
Nelson N. Stone, Vasileios M. Skouteris, and E. David Crawford

Chapter 6: 3D Biopsy: A New Method to Diagnose Prostate Cancer
Kevin Krughoff, Nelson N. Stone, Jesse Elliott, Craig Baer, Paul Arangua, E. David Crawford

Chapter 7: Elastography - Can It Improve Prostate Biopsy Results?
Vassilios M. Skouteris, Spyros D. Yarmenitis, and Georgios P. Zacharopoulos

Chapter 8: Multiparametric MRI of the Prostate as a Tool for Prostate Cancer Detection, Localization, and Risk Assessment
Marc A. Bjurlin, Neil Mendhiratta, and Samir S. Taneja

Chapter 9: Genomic Markers
Neal D. Shore and Karen Ventii

Part Two: Treatment

Chapter 10: Current Status of Clinical Trials in Active Surveillance
Laurence Klotz

Chapter 11: Focused Targeted Therapy in Prostate Cancer
Kevin Krughoff and Al Barqawi

Chapter 12: Technologies and Methods in Primary Ablation with Focal Therapy
Gary Onik

Chapter 13: Multiparametric MRI (mpMRI) – Guided Focal Therapy
Michele Fascelli, Amichai Kilchevsky, Arvin K. George, Peter A. Pinto

Conclusions
Nelson N. Stone and E. David Crawford

Authors

Nelson N. Stone, MD.
Professor of Urology and Radiation Oncology
Department of Urology
The Icahn School of Medicine at Mount Sinai
New York, NY
USA

E. David Crawford, MD
Professor of Urology/Surgery and Radiation Oncology
University of Colorado
Denver, Aurora, CO
USA